Fluorescein Angiography: Basics

Fundus fluorescein angiography (FFA) uses intravenously injected sodium fluorescein dye, which fluoresces under blue excitation light, combined with sequential retinal photography to visualize retinal and choroidal blood flow in real time. It remains a core diagnostic tool for characterizing diabetic retinopathy, retinal vascular occlusions, neovascular age-related macular degeneration, and inflammatory or infectious chorioretinal disease, providing dynamic information about vascular leakage, non-perfusion, and abnormal new vessel growth that structural imaging alone cannot capture.

Before the procedure, informed consent is obtained, reviewing the small but real risk of adverse reactions ranging from mild nausea to rare anaphylaxis, and confirming no relevant allergy or contraindication. The pupils are dilated and baseline color and red-free fundus photographs are taken. Intravenous access is established, typically in an antecubital vein, and a fluorescein bolus is rapidly injected while the photographer begins continuous rapid-sequence imaging timed from the injection. The early transit phases — choroidal flush, arterial, arteriovenous, and venous phases — are captured over the first 20 to 30 seconds, followed by later-phase images at several minutes to assess for progressive leakage or staining. The patient is monitored throughout and immediately following injection for any adverse reaction, and resuscitation equipment and trained personnel must be available given the risk, though rare, of severe reactions.

A normal study shows orderly, symmetric filling of the choroidal, arterial, capillary, and venous circulations with no areas of leakage, pooling, or non-perfusion. Hyperfluorescence can represent true leakage from incompetent vessels, as in diabetic macular edema or choroidal neovascularization; a window defect from retinal pigment epithelium atrophy; pooling in a sub- or intraretinal fluid space; or late staining of a fibrotic or scarred lesion. Hypofluorescence can represent blocked fluorescence from overlying blood or pigment, or true non-perfusion (capillary dropout) as seen in ischemic retinal vascular disease. Neovascularization shows characteristic early hyperfluorescence with progressive leakage or pooling in later frames, distinguishing new, incompetent vessels from normal retinal vasculature.

Common mistakes include failing to obtain adequate informed consent or screen for allergy and contraindication before injecting fluorescein; not having resuscitation equipment and trained staff immediately available; missing the early transit phases due to delayed imaging start relative to the injection; and misinterpreting a window defect as true vascular leakage, or vice versa, without correlating with the clinical picture and other imaging.

The early transit phases provide the most useful information about perfusion status and neovascularization, while later frames are most useful for characterizing leakage and staining. A window defect can mimic true vascular leakage on early frames but, unlike true leakage, does not progressively enlarge or intensify on later frames. OCT angiography, a non-invasive alternative capturing retinal and choroidal vasculature without dye injection, has grown substantially in use, though its findings and correlation with lens status and media clarity differ in important ways from dye-based fluorescein angiography, and the two modalities are often complementary rather than interchangeable.² Deep learning approaches that synthesize angiography-like images directly from non-invasive color fundus photographs are an active area of research, potentially reducing reliance on invasive dye injection in some settings in the future, but these remain investigational and are not yet validated substitutes for true fluorescein angiography in clinical decision-making.¹